Meeting
2013 Genitourinary Cancers Symposium
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
Authors
Susan Halabi
Duke University Medical Center, Durham, NC
Susan Halabi , Chen-Yen Lin , Eric Jay Small , Andrew J. Armstrong , Ellen B. Kaplan , Daniel Peter Petrylak , Cora N. Sternberg , Liji Shen , Stephane Oudard , Johann Sebastian De Bono , A. Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 24)
DOI
10.1200/jco.2013.31.6_suppl.24
Abstract #
24
Poster Bd #
B15
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Giulia Baciarello
Poster
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson
Poster
2018 Genitourinary Cancers Symposium
A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE.
First Author: Carlo Buonerba
Poster
2012 Genitourinary Cancers Symposium
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC‑1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.
First Author: Maha Hussain